
Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors in Phase III NSCLC Trial
Genentech Reports Positive Phase III Krascendo 1 Results Demonstrating Divarasib Improves Survival in Previously Treated KRAS G12C Non-Small Cell Lung Cancer Genentech, a member of the Roche Group, has announced…












